IMTX · Immatics N.V. · Metrics
Market Cap
$1.07B
Shares
152.23M
Volume · Oct 20
1.49M
Avg daily vol (3M)
711.42K
IMTX metrics
57 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$7.51
Market cap
$1.07B
Price action
20 metricsPrice change (1W)
-2.2%
Price change (30D)
-19.2%
Price change (3M)
-23.6%
Price change (6M)
-37.3%
Price change (YTD)
-32.9%
Price change (1Y)
-28.6%
Trailing year
Price change (5Y)
-46.8%
52-week high
$11.87
52-week low
$6.73
Change from 52-week high
-40.6%
Change from 52-week low
+4.8%
Annualized volatility
57.5%
Annualized volatility (3M)
49.4%
Beta
1.4
RSI (14D)
35.8
Price vs SMA 50
-18.1%
Price vs SMA 200
-27.2%
Avg volume (3M)
691,199
Relative volume
1.4
Average dollar volume
$5.88M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
152.23M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.2
reciprocal yield 44.5%
FCF yield
-23.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-23.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$226.78M
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
-441.7%
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
-1,250.0%
Shares change YoY
+10.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-43.5%
Return on assets
-18.6%
Debt / equity
—
Current ratio
7.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$244.45M
Quick ratio
7.5
Interest coverage
-196.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$265.40M
Total assets
$554.56M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$240.14M
Capital expenditures (TTM)
$4.30M
R&D (TTM)
$254.78M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
83
13F filer change QoQ
-2
Institutional ownership
65.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-8.1%
Holder tenure
15.5
Price vs estimated holder cost
+15.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.1%
Short interest
3 metricsShort interest
2.4%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
39 / 100
Insider activity
2 metricsNet insider buying (90D)
$7.50M
Insider-sentiment score
90 / 100
Risk flags
1 metricsGoing concern
—